What is the recommended first‑line systemic estrogen therapy regimen, including dosing and progestogen use for a woman with menopausal vasomotor symptoms or premature bone loss who has no contraindications and an intact uterus?

First-Line Systemic Hormone Therapy for Menopausal Symptoms with Intact Uterus

For a woman with an intact uterus experiencing menopausal vasomotor symptoms or premature bone loss, initiate combined estrogen plus progestogen therapy (EPT), using the lowest effective dose—typically oral estradiol 0.5-1 mg daily or transdermal estradiol 0.025-0.05 mg patch combined with micronized progesterone 100-200 mg daily or another progestogen for endometrial protection. 1

Estrogen Component

The estrogen component should be:

• Oral estradiol 0.5-1 mg daily (starting at lower dose)
• Transdermal estradiol 0.025-0.05 mg patch (preferred if cardiovascular or thrombotic risk factors present)
• Conjugated equine estrogens (CEE) 0.3-0.625 mg daily is an alternative

Transdermal estradiol is preferred over oral formulations when the patient has:

• Moderate cardiovascular disease risk 1
• Elevated VTE risk (transdermal does not increase VTE risk unlike oral) 2
• Metabolic concerns (less adverse metabolic effects) 1

The guideline explicitly recommends transdermal estradiol as first-line for women with moderate CVD risk because these preparations have fewer adverse effects 1. Recent evidence confirms transdermal formulations combined with micronized progesterone do not appear to increase VTE risk 2.

Progestogen Component (Mandatory for Endometrial Protection)

A progestogen MUST be added to prevent endometrial hyperplasia and cancer in women with an intact uterus. 1 Options include:

Preferred:

• Micronized progesterone 100-200 mg daily (oral, at bedtime)
  • Most favorable breast cancer risk profile among progestogens 3
  • Does not adversely modify metabolic parameters 1
  • Additional benefit for sleep quality 4

Alternatives:

• Norethisterone acetate (NETA) 0.1-0.5 mg daily
• Medroxyprogesterone acetate (MPA) 1.5-2.5 mg daily (continuous) or 5-10 mg for 12-14 days/month (cyclic)
• Dydrogesterone 5-10 mg daily

The guideline specifically suggests micronized progesterone or "another progestogen that does not adversely modify metabolic parameters" for women with moderate CVD risk 1. Observational evidence indicates micronized progesterone has a more favorable breast cancer risk profile than synthetic progestins 3.

Dosing Strategy

Start with the lowest effective dose:

• The FDA and major menopause societies recommend using the lowest dose that controls symptoms 1, 5
• Ultra-low-dose options (e.g., estradiol 0.5 mg/NETA 0.1 mg) are effective for symptom relief while potentially reducing risks 6
• Systemic estrogen reduces vasomotor symptoms by approximately 75% 7

Regimen Options

Continuous combined regimen (estrogen + progestogen daily):

• Preferred for postmenopausal women
• Leads to amenorrhea in most women after 6-12 months
• Simpler adherence

Cyclic regimen (estrogen daily + progestogen 12-14 days/month):

• May be used in perimenopausal women still having periods
• Causes predictable withdrawal bleeding

Alternative FDA-Approved Option

Conjugated equine estrogens 0.45 mg/bazedoxifene 20 mg (CEE/BZA) is an alternative that combines estrogen with a selective estrogen receptor modulator instead of a progestogen 1. This formulation:

• Does not increase breast cancer risk (0.25%/year vs 0.23%/year with placebo) 7
• Provides endometrial protection without progestogen
• Effective for vasomotor symptoms and bone loss prevention 1

Critical Eligibility Criteria

This recommendation applies to women who are:

• Age <60 years OR within 10 years of menopause onset 1, 5
• Without contraindications to MHT
• At low-to-moderate cardiovascular risk
• Without history of breast cancer
• Without prior stroke or myocardial infarction 1

For women >60 years or >10 years past menopause onset, the benefit-risk ratio is less favorable due to increased absolute risks of coronary heart disease, stroke, VTE, and dementia 5. In these women, nonhormonal therapies should be considered first 1.

Monitoring and Duration

• Evaluate for unscheduled bleeding to rule out endometrial pathology 1
• Revisit the decision to continue MHT at least annually 1
• Target the shortest total duration consistent with treatment goals 1
• Most women require treatment for >7 years for vasomotor symptoms 7

Important Caveats

Avoid custom-compounded "bioidentical" hormones—use only FDA-approved preparations 1. While FDA-approved bioidentical estrogens (chemically identical to endogenous estrogens) are available and appropriate, custom-compounded formulations lack quality control and standardization.

Breast cancer risk varies by regimen:

• Estrogen-alone (after hysterectomy): neutral to favorable effect 3
• Combined EPT: increased risk with longer use, approximately 1 excess event per 1000 person-years with CEE/MPA 7
• Risk is regimen-specific and lower with micronized progesterone 3

Cardiovascular considerations:

• MHT is NOT indicated for cardiovascular disease prevention 7, 5
• Timing matters: favorable cardiovascular effects when initiated early in menopause 2
• Screen for cardiovascular and breast cancer risk before initiating 1